XCSport体育
About Henlius
Company Profile
Corporate Culture
Honor
Board of Directors
Management Team
Advisory Committee
Product
Marketed Products
XCSport体育:Products in R&D
XCSport体育:Clinical Trial
Science & Technology
R&D Result
XCSport体育:Innovation Centre
Technology Platform
Quality Management
Manufacturing
Collaborations
Investor Relations
Information Disclosure
Corporate Governance
XCSport体育:Financial Reports
XCSport体育:Stock Info
XCSport体育:IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
XCSport体育:Press Release
XCSport体育:Multi-media
Media Reports
Media Enquiry
Careers
Talent Philosophy
Staff Life
Training and Development
Job Opportunities
Contact Us
Contact Information
Customer Message
Privacy
Legal Statement
Compliance
EN
简体
EN
繁體
Home
XCSport体育:About Henlius
XCSport体育:Company Profile
Corporate Culture
Honor
Board of Directors
XCSport体育:Management Team
Advisory Committee
Product
Marketed Products
XCSport体育:Products in R&D
Clinical Trial
Science & Technology
XCSport体育:R&D Result
XCSport体育:Innovation Centre
XCSport体育:Technology Platform
XCSport体育:Quality Management
Manufacturing
XCSport体育:Collaborations
Investor Relations
Information Disclosure
Listing Documents
Announcement & Circulars
Corporate Governance
Financial Reports
Stock Info
XCSport体育:IR Calendar
Investor Presentation
Analyst Coverage
Contact Information
Media
Press Release
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
Event
Popular Science
Media Reports
Media Enquiry
Careers
Talent Philosophy
XCSport体育:Staff Life
Training and Development
Job Opportunities
Contact Us
XCSport体育:Contact Information
Customer Message
Privacy
XCSport体育:Legal Statement
Compliance
搜索
Be the most trusted biotech company
XCSport体育:Press Release
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Multi-media
Company
XCSport体育:Popular Science
XCSport体育:Highlights
Download
Media Reports
Media Enquiry
2021-12-17
NMPA Has Accepted The NDA of HLX01(Rituximab Injection) for the Treatment of Rheumatoid Arthritis
2021-12-07
Henlius Adalimumab Biosimilar 汉达远® Approved by NMPA
2021-11-20
Henlius Released Phase 3 Study Data of its Bevacizumab Biosimilar HLX04 at ESMO Asia 2020
2021-11-12
The IND Application of Henlius Daratumumab Biosimilar Accepted by NMPA
2021-11-09
First Patient Dosed in Phase 1 Clinical Trial of Henlius Denosumab Biosimilar HLX14
2021-11-06
Henlius ACE2-Fc Fusion Protein HLX71 Received IND Approval from US FDA
2021-10-29
The Results of the Phase 3 Study of Henlius’ Adalimumab Biosimilar HLX03 Presented on EADV 2020
2021-10-15
Henlius and Essex Enter into a Global Co-Development and Exclusive License Agreement, to Jointly Develop Bevacizumab to Treat Ophthalmic Diseases
2021-10-05
Investigational New Drug Application of Henlius SARS-CoV-2 Neutralizing Antibody HLX70 Approved by US FDA
1
2
3
...
5